3T MRI in Patients With Deep Brain Stimulation (DBS)
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · May 11, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how deep brain stimulation (DBS), a treatment used for conditions like advanced Parkinson's disease and certain movement disorders, affects brain function. Researchers want to use a special type of MRI called functional MRI (fMRI) to get better images of the brain and understand how DBS changes its activity. This could help improve treatment approaches for various neurological and psychiatric disorders, such as epilepsy and depression.
To participate in this study, candidates should be between 18 and 85 years old and either have planned or already received DBS electrode implantation. It's important that participants can understand the study's goals and give their consent. Those with serious cognitive or speech issues that prevent them from communicating effectively may not be eligible. If you join the study, you can expect to undergo fMRI scans that will help researchers learn more about how DBS impacts the brain. This research aims to enhance our understanding of brain functioning, even though participants may not receive any direct benefits from being part of the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 85 years of age
- • Participants must be planned to undergo, or have undergone implantation of DBS electrodes
- • Participants must be able to understand the purpose of this research and must sign the informed consent form.
- • Participants must understand that the role of this research is to enhance our understanding of brain functioning and that he/she will not directly or indirectly benefit from the study.
- Exclusion Criteria:
- • Participants who have serious cognitive or psychological impairments and cannot give informed consent.
- • Participants who are unable to effectively or efficiently communicate, for example patients suffering from speech deficits (dysarthria, aphasia) or are non-English speaking.
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Andres Lozano
Principal Investigator
University Health Network, Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials